BBP vs. TXG

Last updated Apr 1, 2026

Compare and contrast key facts about Virtus LifeSci Biotech Products ETF (BBP) and 10x Genomics, Inc. (TXG).

BBP is a passively managed fund by Virtus Investment Partners that tracks the performance of the LifeSci Biotechnology Products Index. It was launched on Dec 17, 2014.

Performance

BBP vs. TXG - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Virtus LifeSci Biotech Products ETF (BBP) and 10x Genomics, Inc. (TXG). The values are adjusted to include any dividend payments, if applicable.

BBP vs. TXG - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019
BBP Virtus LifeSci Biotech Products ETF	3.94%	33.15%	3.32%	17.88%	0.85%	-8.17%	22.24%	14.29%
TXG 10x Genomics, Inc.	30.17%	13.58%	-74.34%	53.57%	-75.54%	5.20%	85.70%	44.55%

Returns By Period

In the year-to-date period, BBP achieves a 3.94% return, which is significantly lower than TXG's 30.17% return.

BBP

• 1D: 5.93%
• 1M: -2.16%
• YTD: 3.94%
• 6M: 18.71%
• 1Y: 41.70%
• 3Y*: 19.01%
• 5Y*: 9.37%
• 10Y*: 12.76%

TXG

• 1D: 7.17%
• 1M: -7.90%
• YTD: 30.17%
• 6M: 81.61%
• 1Y: 143.18%
• 3Y*: -27.53%
• 5Y*: -35.20%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

BBP vs. TXG — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BBP

BBP Risk / Return Rank: 82
BBP Sharpe Ratio Rank: 81
BBP Sortino Ratio Rank: 83
BBP Omega Ratio Rank: 73
BBP Calmar Ratio Rank: 87
BBP Martin Ratio Rank: 87

TXG

TXG Risk / Return Rank: 89
TXG Sharpe Ratio Rank: 91
TXG Sortino Ratio Rank: 89
TXG Omega Ratio Rank: 83
TXG Calmar Ratio Rank: 92
TXG Martin Ratio Rank: 90

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BBP vs. TXG - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Virtus LifeSci Biotech Products ETF (BBP) and 10x Genomics, Inc. (TXG). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	BBP	TXG	Difference
Sharpe ratio Return per unit of total volatility	1.55	2.02	-0.47
Sortino ratio Return per unit of downside risk	2.18	2.72	-0.54
Omega ratio Gain probability vs. loss probability	1.27	1.31	-0.04
Calmar ratio Return relative to maximum drawdown	2.69	4.48	-1.79
Martin ratio Return relative to average drawdown	10.18	10.60	-0.42
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

BBP vs. TXG - Sharpe Ratio Comparison

The current BBP Sharpe Ratio is 1.55, which is comparable to the TXG Sharpe Ratio of 2.02. The chart below compares the historical Sharpe Ratios of BBP and TXG, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	BBP	TXG	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.55	2.02	-0.47
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.36	-0.52	+0.88
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.47	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.39	-0.20	+0.59

Correlation

The correlation between BBP and TXG is 0.48, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Dividends

BBP vs. TXG - Dividend Comparison

Neither BBP nor TXG has paid dividends to shareholders.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
BBP Virtus LifeSci Biotech Products ETF	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.18%	0.00%	1.29%
TXG 10x Genomics, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Drawdowns

BBP vs. TXG - Drawdown Comparison

The maximum BBP drawdown since its inception was -44.32%, smaller than the maximum TXG drawdown of -96.47%. Use the drawdown chart below to compare losses from any high point for BBP and TXG.

Drawdown Indicators

	BBP	TXG	Difference
Max Drawdown Largest peak-to-trough decline	-44.32%	-96.47%	+52.15%
Max Drawdown (1Y) Largest decline over 1 year	-13.38%	-28.03%	+14.65%
Max Drawdown (5Y) Largest decline over 5 years	-38.28%	-96.47%	+58.19%
Max Drawdown (10Y) Largest decline over 10 years	-44.32%	—	—
Current Drawdown Current decline from peak	-3.90%	-89.51%	+85.61%
Average Drawdown Average peak-to-trough decline	-12.16%	-58.85%	+46.69%
Ulcer Index Depth and duration of drawdowns from previous peaks	3.72%	11.85%	-8.13%

Volatility

BBP vs. TXG - Volatility Comparison

The current volatility for Virtus LifeSci Biotech Products ETF (BBP) is 11.21%, while 10x Genomics, Inc. (TXG) has a volatility of 22.60%. This indicates that BBP experiences smaller price fluctuations and is considered to be less risky than TXG based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	BBP	TXG	Difference
Volatility (1M) Calculated over the trailing 1-month period	11.21%	22.60%	-11.39%
Volatility (6M) Calculated over the trailing 6-month period	18.03%	51.34%	-33.31%
Volatility (1Y) Calculated over the trailing 1-year period	27.16%	71.82%	-44.66%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	26.23%	68.47%	-42.24%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	27.51%	66.81%	-39.30%